Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 2/20 | 0.66 |
| ▸ | SYK | P43405 | 2/20 | 0.66 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.66 |
| ▸ | BRSK1 | Q8TDC3 | 1/20 | 0.66 |
| ▸ | FES | P07332 | 1/20 | 0.56 |
| ▸ | FER | P16591 | 1/20 | 0.56 |
| ▸ | FRK | P42685 | 1/20 | 0.56 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.56 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.56 |
| ▸ | NAPEPLD | Q6IQ20 | 6/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3100746 | 0.89 | TYK2 (0.67) | TYK2SYKIRAK4BRSK1FES | |
| SCHEMBL3110587 | 0.88 | TYK2 (0.68) | TYK2SYKIRAK4BRSK1FES | |
| SCHEMBL428624 | 0.86 | TYK2 (0.56) | TYK2SYKIRAK4BRSK1FES | |
| SCHEMBL427148 | 0.83 | TYK2 (0.62) | TYK2SYKIRAK4BRSK1FES | |
| SCHEMBL11929833 | 0.82 | TYK2 (0.72) | TYK2SYKIRAK4BRSK1FES | |
| SCHEMBL428778 | 0.82 | TYK2 (0.60) | TYK2SYKIRAK4BRSK1FES | |
| SCHEMBL12634088 | 0.81 | TYK2 (0.70) | TYK2SYKIRAK4BRSK1FES | |
| SCHEMBL3121609 | 0.80 | PIK3CA (0.44) | SYKNAPEPLDPIK3CAPIK3CB | |
| SCHEMBL3110596 | 0.80 | TYK2 (0.75) | TYK2SYKIRAK4BRSK1FES | |
| SCHEMBL30273129 | 0.80 | TYK2 (0.72) | TYK2SYKIRAK4BRSK1FES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236795-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-07 | — | — | US | disclosed |
| US-7935698-B2 | Heteroaryl-hydrazone compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935698-B2 | Heteroaryl-hydrazone compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935698-B2 | Heteroaryl-hydrazone compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-05-03 | — | — | US | disclosed |
| US-20100256132-A1 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2010-10-07 | — | — | US | disclosed |
| US-7696202-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2010-04-13 | — | — | US | disclosed |
| EP-1689403-A4 | HETEROARYL-HYDRAZONE COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2007-09-05 | — | — | EP | disclosed |
| EP-1689403-A2 | HETEROARYL-HYDRAZONE COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20050282809-A1 | Heteroaryl-hydrazone compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2005-12-22 | — | — | US | disclosed |
| WO-2005046604-A2 | HETEROARYL-HYDRAZONE COMPOUNDS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282809-A1 | Heteroaryl-hydrazone compounds | MMP12, IL1RN, CASP12 | TYK2 3469/4885SYK 3362/4885IRAK4 639/4885 |
| US-20100256132-A1 | IL-12 MODULATORY COMPOUNDS | IL2, IL4, IFNG | TYK2 1186/4885SYK 1075/4885IRAK4 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.